AgonOx
AgonOx is a biotechnology company dedicated to discovering and developing new immunotherapy treatments to improve the lives of cancer patients. They focus on harnessing the power of the immune system, particularly T cells, to target and destroy tumors. Their research involves identifying new immunotherapy targets, developing recombinant proteins, antibodies, and small molecules, and testing these agents in human assays and mouse models. They have a pipeline of immunotherapy drugs, including the AGX-148 TIL therapy and the OX40 platform, with collaborations and clinical trials underway.
Industries
Nr. of Employees
small (1-50)
Patents
Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
US-11572541-B2
View Details
Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
US-11572541-B2
View DetailsProducts
Autologous tumor-infiltrating lymphocyte (TIL) therapy program
A program to generate autologous TIL products by selecting and expanding tumor-reactive T cells from patients' fresh tumor tissue for adoptive cell therapy in solid malignancies.
Autologous tumor-infiltrating lymphocyte (TIL) therapy program
A program to generate autologous TIL products by selecting and expanding tumor-reactive T cells from patients' fresh tumor tissue for adoptive cell therapy in solid malignancies.
Services
Partnership-based support for initiating clinical studies of adoptive T cell therapies, including site initiation and cooperative study conduct with clinical research centers and industry partners.
Development and execution of immune-specific in-vitro assays and murine tumor models to evaluate candidate immunotherapies and TIL products.
Partnership-based support for initiating clinical studies of adoptive T cell therapies, including site initiation and cooperative study conduct with clinical research centers and industry partners.
Development and execution of immune-specific in-vitro assays and murine tumor models to evaluate candidate immunotherapies and TIL products.
Expertise Areas
- Tumor-infiltrating lymphocyte (TIL) therapy development
- Adoptive cell therapy manufacturing and ex-vivo expansion
- Immunotherapy target discovery and validation
- Biomarker discovery and gene expression profiling
Key Technologies
- Flow cytometry / cell sorting
- Ex-vivo T cell expansion protocols
- Gene expression microarray / RNA profiling
- Self-delivering RNAi for ex-vivo gene silencing
News & Updates
A clinical trial to assess the safety and potential therapeutic benefit of PH-762 treated TILs in melanoma and other solid tumors, conducted at Providence Cancer Institute.
Daiichi Sankyo collaborates with AgonOx on preclinical development of an undisclosed immuno-oncology target, with potential for worldwide research, development, and commercialization.
AgonOx's OX40 platform is being used in a Phase 1 trial of MedImmune’s humanized OX40 agonist, MEDI6383, to evaluate safety and anti-tumor effects.
AgonOx entered a global partnership with MedImmune to develop OX40 agonists for cancer therapy, supporting further research and clinical studies.
AgonOx received a patent for OX40 Ligand Fusion Proteins, which enhance tumor-specific T-cell immunity, adding to their intellectual property portfolio.
A clinical trial to assess the safety and potential therapeutic benefit of PH-762 treated TILs in melanoma and other solid tumors, conducted at Providence Cancer Institute.
Daiichi Sankyo collaborates with AgonOx on preclinical development of an undisclosed immuno-oncology target, with potential for worldwide research, development, and commercialization.
AgonOx's OX40 platform is being used in a Phase 1 trial of MedImmune’s humanized OX40 agonist, MEDI6383, to evaluate safety and anti-tumor effects.
AgonOx entered a global partnership with MedImmune to develop OX40 agonists for cancer therapy, supporting further research and clinical studies.
AgonOx received a patent for OX40 Ligand Fusion Proteins, which enhance tumor-specific T-cell immunity, adding to their intellectual property portfolio.